Need Help? Chat Now With a Live Representative!

Preferred Provider Status for Atlantic Research Group

Preferred Provider Status for Atlantic Research Group

Preferred Provider Status for Atlantic Research Group

February 1, 2018

Challenge: A specialty biopharmaceutical company targeting the therapeutic power of plasma for the treatment of chronic, life-altering diseases like hemophilia and immune deficiencies, contracted with ARG to perform CRO services for two different Phase III studies. Regulatory requirements included an audit mid-way through the process.

Results: ARG won preferred provider status after successfully completing an audit of protocol design, conduct, monitoring, data management, and quality assurance processes.

Lessons Learned: Equal expertise is multiple functional areas clearly demonstrates ARG team experience, commitment, and execution.

ARG rescues Phase I oncology trial using TrialVista® CTMS

ARG rescues Phase I oncology trial using TrialVista® CTMS

Challenge: A leading specialty pharmaceutical company focused on the development and commercialization of next generation therapies for cancer and immunomodulatory […]

March 1, 2018
ARG successfully starts up a Phase II trial within 6 weeks

ARG successfully starts up a Phase II trial within 6 weeks

Challenge: In an economic downturn, small biotech companies often depend on clinical milestones in order to maximize shareholder value and […]

May 1, 2018
Pivotal Phase III trial undergoes audits by the FDA and sponsor

Pivotal Phase III trial undergoes audits by the FDA and sponsor

Challenge: A pivotal Phase III clinical trial of C1 inhibitor for the prophylactic treatment of hereditary angioedema managed by ARG […]

June 1, 2018
GO TO TOP